Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Brief description of study

This study employs a multi-center approach to evaluate cutaneous vasculitis across several forms of idiopathic vasculitis. Patients with cutaneous manifestations of vasculitis will be evaluated by teams of primary vasculitis care providers and Dermatologists in order to facilitate optimal selection of patients and sampling of lesions. A punch skin biopsy at a site of active vasculitis will be the source of material for histopathologic and transcriptomic evaluation. The histopathology of cutaneous vasculitis will be characterized using a standardized, systematic approach. This approach includes a detailed description of abnormalities and extensive immunophenotyping of cell populations in the epidermal, dermal, and subcutaneous layers of skin. In addition to histologic description, skin biopsy material will be used a source of RNA for whole-genome gene expression profiling studies. Differential gene expression comparisons will be made across types of vasculitis. Disease-agnostic computational approaches will be used to discover novel ways to classify subgroups based upon global and specific patterns of gene expression. Additional samples will be collected (whole blood RNA, DNA) for potential secondary studies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    ['Cryoglobulinemic Vasculitis (CV)', 'Drug-induced Vasculitis', 'Eosinophilic Granulomatosis With Polyangiitis (EGPA)', 'IgA Vasculitis', 'Isolated Cutaneous Vasculitis', 'Granulomatosis With Polyangiitis (GPA)', 'Microscopic Polyangiitis (MPA)', 'Polyarteritis Nodosa (PAN)', 'Urticarial Vasculitis', 'Vasculitis']
  • Age: - 99 Years
  • Gender: All
Updated on 09 Mar 2024. Study ID: 825969

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center